Can Duphaston (dydrogesterone) be prescribed to a pregnant woman with two prior consecutive spontaneous abortions as luteal‑phase support, and what is the recommended dose and duration?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Duphaston (Dydrogesterone) for Recurrent Pregnancy Loss

Dydrogesterone 10 mg twice daily should be started immediately upon pregnancy confirmation and continued until 12 weeks of gestation in women with two or more consecutive spontaneous abortions, based on evidence showing a significant reduction in miscarriage rates from 29% to 13.4%. 1

Evidence-Based Dosing and Duration

  • The recommended dose is dydrogesterone 10 mg orally twice daily (20 mg total daily dose), initiated as soon as pregnancy is confirmed and continued through the 12th gestational week. 1

  • This regimen demonstrated statistically significant reduction in abortion rates compared to no treatment in women with a mean history of 3.5 prior spontaneous abortions (p ≤ 0.05). 1

  • Treatment should begin as early as possible after pregnancy confirmation to maximize benefit during the critical implantation and early placental development period. 1, 2

Mechanism and Safety Profile

  • Dydrogesterone is an oral retroprogesterone with high bioavailability and selective progesterone receptor activity, making it particularly suitable for early pregnancy support. 2, 3

  • The medication modulates maternal immune response by increasing T-helper 2 cytokines (IL-4, IL-6) while decreasing interferon-gamma, creating a favorable immunological environment for embryo acceptance. 4

  • No increased risk of pregnancy complications or congenital abnormalities has been observed with dydrogesterone use in early pregnancy. 1, 2

Critical Distinction from Preterm Birth Prevention

Important caveat: Dydrogesterone for recurrent miscarriage is NOT the same indication as progesterone for preterm birth prevention. The evidence provided shows:

  • For women with prior spontaneous preterm birth (not miscarriage), 17-alpha-hydroxyprogesterone caproate (17P) 250 mg intramuscularly weekly from 16-20 weeks until 36 weeks is the recommended therapy. 5, 6, 7

  • Vaginal progesterone is indicated for short cervical length (≤20 mm) detected at 18-24 weeks, not for recurrent first-trimester losses. 8, 6

Clinical Implementation

  • Begin dydrogesterone 10 mg twice daily immediately when pregnancy test is positive in women with ≥2 consecutive spontaneous abortions. 1

  • Continue treatment through gestational week 12, when the placenta assumes progesterone production. 1, 2

  • Standard prenatal care should be provided concurrently; dydrogesterone is an adjunct to, not a replacement for, comprehensive obstetric management. 1

  • The medication has demonstrated efficacy specifically in unexplained recurrent spontaneous abortion, with a well-established safety profile spanning decades of clinical use. 2, 3

References

Research

Dydrogesterone in the reduction of recurrent spontaneous abortion.

The Journal of steroid biochemistry and molecular biology, 2005

Research

Dydrogesterone use in early pregnancy.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2016

Research

The role of dydrogesterone in recurrent (habitual) abortion.

The Journal of steroid biochemistry and molecular biology, 2005

Guideline

Preterm Birth Prevention with Progesterone

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Peri‑operative Management of Progesterone Therapy in Pregnant Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

Is Duphaston (dydrogesterone) appropriate for a patient with early pregnancy and no fetal heartbeat (anembryonic or missed miscarriage)?
Can oral and vaginal progesterone be administered simultaneously?
In a first‑trimester pregnant woman with a focal uterine contraction on ultrasound but no vaginal bleeding, cervical shortening, or open cervical os, is progesterone therapy (Duphaston – dydrogesterone) indicated?
How should Duphaston (dydrogesterone) be dosed for luteal‑phase support or menstrual disorders, and what are its contraindications and common side effects?
What oral progesterone dose is recommended for a woman with recurrent pregnancy loss?
Should I first see the referred colorectal/general surgeon for evaluation before scheduling incision and drainage of my perineal abscess (currently on amoxicillin‑clavulanate and awaiting MRI), or can I directly schedule the surgery?
What urethral catheter size is appropriate for a 1‑year‑6‑month‑old child?
How should a child be managed after a possible rabies exposure from an animal bite or scratch?
What is the appropriate allopurinol dosing regimen to start before cytoreductive chemotherapy, including adjustments for impaired renal function (creatinine clearance <30 mL/min) and pediatric patients?
Does paternal genetic contribution cause nausea and vomiting (morning sickness) during pregnancy?
Can an adult with stable, non‑inflammatory rosacea (persistent flushing or telangiectasia without active lesions) safely undergo Dermapen 4 microneedling, and if so, what needle depth and pre‑treatment regimen are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.